** Shares of drugmaker Vanda Pharmaceuticals fall 10.9% to $4.41 premarket
** Co says U.S. FDA declined to approve its stomach paralysis drug, tradipitant
** Co says the FDA suggested that Vanda conduct additional studies
** Will continue to pursue approval for the drug to treat gastroparesis, characterized by delayed gastric emptying
** Plans to submit separate marketing application for tradipitant to prevent vomiting during motion sickness later this year
** Stock up 17.3% YTD vs 11.3% rise in the Nasdaq Biotechnology Index
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。